Primary myelofibrosis (PMF) is a clonal hematologic malignancy characterized by BM fibrosis, extramedullary hematopoiesis, circulating CD34+ cells, splenomegaly, and a propensity to evolve to acute myeloid leukemia. Moreover, the spleen and BM of patients harbor atypical, clustered megakaryocytes, which contribute to the disease by secreting profibrotic cytokines. Here, we have revealed that megakaryocytes in PMF show impaired maturation that is associated with reduced GATA1 protein. In investigating the cause of GATA1 downregulation, our gene-expression study revealed the presence of the
Laure Gilles, Ahmet Dirim Arslan, Christian Marinaccio, Qiang Jeremy Wen, Priyanka Arya, Maureen McNulty, Qiong Yang, Jonathan C. Zhao, Katerina Konstantinoff, Terra Lasho, Animesh Pardanani, Brady Stein, Isabelle Plo, Sriram Sundaravel, Amittha Wickrema, Annarita Migliaccio, Sandeep Gurbuxani, William Vainchenker, Leonidas C. Platanias, Ayalew Tefferi, John D. Crispino
Title and authors | Publication | Year |
---|---|---|
High Mobility Group A1 Chromatin Keys: Unlocking the Genome During MPN Progression
Resar LM, Luo LZ |
International Journal of Molecular Sciences | 2025 |
Delivery of miR-15b-5p via magnetic nanoparticle-enhanced bone marrow mesenchymal stem cell-derived extracellular vesicles mitigates diabetic osteoporosis by targeting GFAP
Xu C, Wang Z, Liu Y, Duan K, Guan J |
Cell Biology and Toxicology | 2024 |
Association between PDCD6-VNTR polymorphism and urinary cancer susceptibility.
Yang GE, Kim MH, Jeong MS, Lee SY, Choi YH, Nam JK, Kim TN, Leem SH |
Genes & genomics | 2024 |
Reduced GATA1 levels are associated with ineffective erythropoiesis in sickle cell anemia
El Hoss S, Shangaris P, Brewin J, Psychogyiou ME, Ng C, Pedler L, Rooks H, Gotardo ÉM, Gushiken LF, Brito PL, Nicolaides KH, Conran N, Rees DC, Strouboulis J |
Haematologica | 2024 |
Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer
Blatti C, de la Fuente J, Gao H, Marín-Goñi I, Chen Z, Zhao SD, Tan W, Weinshilboum R, Kalari KR, Wang L, Hernaez M |
Cancer research | 2023 |
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.
Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, Rameau P, Catelain C, Alfaro A, Edmond V, Signolle N, Marchand V, Droin N, Hoogenboezem R, Schneider RK, Penson A, Abdel-Wahab O, Giraudier S, Pasquier F, Marty C, Plo I, Villeval JL, Constantinescu SN, Porteu F, Vainchenker W, Solary E |
Leukemia | 2023 |
GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosis
Gobbo F, Zingariello M, Verachi P, Falchi M, Arciprete F, Martelli F, Peli A, Mazzarini M, Vierstra J, Mead-Harvey C, Dueck AC, Sarli G, Nava S, Sgalla G, Richeldi L, Migliaccio AR |
2023 | |
Perspectives of current understanding and therapeutics of Diamond-Blackan anemia.
Liu Y, Karlsson S |
Leukemia | 2023 |
Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape
Mahmud M, Vasireddy S, Gowin K, Amaraneni A |
International journal of molecular sciences | 2023 |
A Congenital Anemia Reveals Distinct Targeting Mechanisms for Master Transcription Factor GATA1
L Ludwig, C Lareau, E Bao, N Liu, T Utsugisawa, A Tseng, S Myers, J Verboon, J Ulirsch, W Luo, C Muus, C Fiorini, M Olive, C Vockley, M Munschauer, A Hunter, H Ogura, T Yamamoto, H Inada, S Nakagawa, S Ozono, V Subramanian, R Chiarle, B Glader, S Carr, M Aryee, A Kundaje, S Orkin, A Regev, T McCavit, H Kanno, V Sankaran |
Blood | 2022 |
SENP1 promotes triple-negative breast cancer invasion and metastasis via enhancing CSN5 transcription mediated by GATA1 deSUMOylation
Y Gao, R Wang, J Liu, K Zhao, X Qian, X He, H Liu |
International journal of biological sciences | 2022 |
The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice
P Verachi, F Gobbo, F Martelli, A Martinelli, G Sarli, A Dunbar, R Levine, R Hoffman, M Massucci, L Brandolini, C Giorgio, M Allegretti, A Migliaccio |
Frontiers in Oncology | 2022 |
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis
Varricchio L, Hoffman R |
Frontiers in Oncology | 2022 |
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
Li L, Kim JH, Lu W, Williams DM, Kim J, Cope L, Rampal RK, Koche RP, Xian L, Luo LZ, Vasiljevic M, Matson DR, Zhao ZJ, Rogers O, Stubbs MC, Reddy K, Romero AR, Psaila B, Spivak JL, Moliterno AR, Resar LMS |
Blood | 2022 |
Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis.
Hatzimichael E, Timotheatou D, Koumpis E, Benetatos L, Makis A |
2022 | |
Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A, Gangat N, Pardanani A, Crispino JD |
Cancer research | 2022 |
Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1(low) mouse model.
Verachi P, Gobbo F, Martelli F, Falchi M, di Virgilio A, Sarli G, Wilke C, Bruederle A, Prahallad A, Arciprete F, Zingariello M, Migliaccio AR |
Experimental Hematology | 2022 |
The Role of Megakaryocytes in Myelofibrosis
J Melo-Cardenas, AR Migliaccio, JD Crispino |
Hematology/Oncology Clinics of North America | 2021 |
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
JL Spivak, AR Moliterno |
Frontiers in Oncology | 2021 |
hGATA1 Under the Control of a μLCR/β-Globin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Gata1low Mutation in Mice
F Martelli, P Verachi, M Zingariello, M Mazzarini, AM Vannucchi, A Lonetti, B Bacci, G Sarli, AR Migliaccio |
Frontiers in Genetics | 2021 |
Disease modifying agents of myeloproliferative neoplasms: a review
SE Lee |
Blood Research | 2021 |
Role of β1 integrin in thrombocytopoiesis
M Mazzarini, P Verachi, F Martelli, AR Migliaccio |
2021 | |
A patient with a germline GATA2 mutation and primary myelofibrosis
CV Rütsche, E Haralambieva, V Lysenko, S Balabanov, AP Theocharides |
Blood Advances | 2021 |
A Novel Megakaryocyte Subpopulation Poised to Exert the Function of HSC Niche as Possible Driver of Myelofibrosis
AR Migliaccio |
Cells | 2021 |
TLR7 ligation augments hematopoiesis in Rps14 (uS11) deficiency via paradoxical suppression of inflammatory signaling
O Peña, A Lubin, C Hockings, J Rowell, Y Jung, Y Hoade, P Dace, L Valdivia, K Tuschl, C Böiers, M Virgilio, S Richardson, E Payne |
Blood Advances | 2021 |
Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
M Zingariello, V Rosti, AM Vannucchi, P Guglielmelli, M Mazzarini, G Barosi, ML Genova, AR Migliaccio |
Frontiers in Oncology | 2020 |
Management of myelofibrosis after ruxolitinib failure
P Bose, S Verstovsek |
Leukemia & Lymphoma | 2020 |
Integrated analyses of translatome and proteome identify the rules of translation selectivity in RPS14-deficient cells
I Boussaid, SL Goff, C Floquet, EF Gautier, A Raimbault, PJ Viailly, DA Dulaimi, B Burroni, I Dusanter-Fourt, I Hatin, P Mayeux, B Cosson, M Fontenay |
Haematologica | 2020 |
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
J Grabek, J Straube, M Bywater, SW Lane |
Cells | 2020 |
Sexual dimorphism in aging hematopoiesis: an earlier decline of hematopoietic stem and progenitor cells in male than female mice
EY So, EM Jeong, KQ Wu, PM Dubielecka, AM Reginato, PJ Quesenberry, OD Liang |
Aging | 2020 |
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
P Bose, L Masarova, S Verstovsek |
Cancers | 2020 |
Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy
Piasecki A, Leiva O, Ravid K |
Archives of stem cell and therapy | 2020 |
The mechanisms of pathological extramedullary hematopoiesis in diseases.
Yang X, Chen D, Long H, Zhu B |
Cellular and molecular life sciences : CMLS | 2020 |
The Pleiotropic Effects of GATA1 and KLF1 in Physiological Erythropoiesis and in Dyserythropoietic Disorders
G Barbarani, C Fugazza, J Strouboulis, AE Ronchi |
Frontiers in physiology | 2019 |
New Concepts of Treatment for Patients with Myelofibrosis
P Bose, M Alfayez, S Verstovsek |
Current Treatment Options in Oncology | 2019 |
Impaired human hematopoiesis due to a cryptic intronic GATA1 splicing mutation
NJ Abdulhay, C Fiorini, JM Verboon, LS Ludwig, JC Ulirsch, B Zieger, CA Lareau, X Mi, A Roy, EA Obeng, M Erlacher, N Gupta, SB Gabriel, BL Ebert, CM Niemeyer, RN Khoriaty, P Ancliff, HT Gazda, MW Wlodarski, VG Sankaran |
Journal of Experimental Medicine | 2019 |
Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?
RT Piszczatowski, U Steidl |
Clinical cancer research | 2019 |
Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks
S Sundaravel, WL Kuo, JJ Jeong, GS Choudhary, S Gordon-Mitchell, H Liu, TD Bhagat, KL McGraw, S Gurbuxani, AF List, A Verma, A Wickrema |
Clinical cancer research | 2019 |
Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology
Z Eran, M Zingariello, MT Bochicchio, C Bardelli, AR Migliaccio |
F1000Research | 2019 |
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
P Bose |
Expert Opinion on Orphan Drugs | 2019 |
Novel targets to cure primary myelofibrosis from studies on Gata1low mice
M Zingariello, F Martelli, P Verachi, C Bardelli, F Gobbo, M Mazzarini, AR Migliaccio |
IUBMB Life | 2019 |
Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice
O Leiva, SK Ng, S Matsuura, V Chitalia, H Lucero, A Findlay, C Turner, W Jarolimek, K Ravid |
International Journal of Hematology | 2019 |
Mechanisms of erythrocyte development and regeneration: implications for regenerative medicine and beyond
EH Bresnick, KJ Hewitt, C Mehta, S Keles, RF Paulson, KD Johnson |
Development (Cambridge, England) | 2018 |
GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy
T Ling, JD Crispino, M Zingariello, F Martelli, AR Migliaccio |
Expert Review of Hematology | 2018 |
Management of Myelofibrosis-Related Cytopenias
P Bose, S Verstovsek |
Current Hematologic Malignancy Reports | 2018 |
Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis
MK Song, BB Park, JE Uhm |
International journal of molecular sciences | 2018 |
The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature
M Zingariello, L Sancillo, F Martelli, F Ciaffoni, M Marra, L Varricchio, RA Rana, C Zhao, JD Crispino, AR Migliaccio |
Blood Cancer Journal | 2017 |